In situ growth in early lung adenocarcinoma may represent precursor growth or invasive clone outgrowth-a clinically relevant distinction.


Journal

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605

Informations de publication

Date de publication:
07 2019
Historique:
received: 04 10 2018
accepted: 04 03 2019
revised: 04 03 2019
pubmed: 2 4 2019
medline: 28 4 2020
entrez: 2 4 2019
Statut: ppublish

Résumé

The switch from in situ to invasive tumor growth represents a crucial stage in the evolution of lung adenocarcinoma. However, the biological understanding of this shift is limited, and 'Noguchi Type C' tumors, being early lung adenocarcinomas with mixed in situ and invasive growth, represent those that are highly valuable in advancing our understanding of this process. All Noguchi Type C adenocarcinomas (n = 110) from the LATTICE-A cohort were reviewed and two patterns of in situ tumor growth were identified: those deemed likely to represent a true shift from precursor in situ to invasive disease ('Noguchi C1') and those in which the lepidic component appeared to represent outgrowth of the invasive tumor along existing airspaces ('Noguchi C2'). Overall Ki67 fraction was greater in C2 tumors and only C1 tumors showed significant increasing Ki67 from in situ to invasive disease. P53 positivity was acquired from in situ to invasive disease in C1 tumors but both components were positive in C2 tumors. Likewise, vimentin expression was increased from in situ to invasive tumor in C1 tumors only. Targeted next generation sequencing of 18 C1 tumors identified four mutations private to the invasive regions, including two in TP53, while 6 C2 tumors showed no private mutations. In the full LATTICe-A cohort, Ki67 fraction classified as either less than or greater than 10% within the in situ component of lung adenocarcinoma was identified as a strong predictor of patient outcome. This supports the proposition that tumors of all stages that have 'high grade' in situ components represent those with aggressive lepidic growth of the invasive clone. Overall these data support that the combined growth of Noguchi C tumors can represent two differing biological states and that 'Noguchi C1' tumors represent the genuine biological shift from in situ to invasive disease.

Identifiants

pubmed: 30932019
doi: 10.1038/s41379-019-0257-1
pii: S0893-3952(22)01027-4
doi:

Substances chimiques

Biomarkers, Tumor 0
Ki-67 Antigen 0
MKI67 protein, human 0
TP53 protein, human 0
Tumor Suppressor Protein p53 0
VIM protein, human 0
Vimentin 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1095-1105

Subventions

Organisme : Medical Research Council
ID : MC_UP_1203/1
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C1362/A18081
Pays : United Kingdom

Auteurs

David Allan Moore (DA)

University College London Cancer Institute, 72 Huntley Street, London, WC1E 6HX, UK.
Department of Histopathology, University College London Hospitals NHS Foundation Trust, London, NW1 2BU, UK.

Marco Sereno (M)

MRC Toxicology Unit, University of Cambridge, Leicester, LE1 7HB, UK.
Leicester Cancer Research Centre, University of Leicester, Leicester, LE2 7LX, UK.

Madhumita Das (M)

MRC Toxicology Unit, University of Cambridge, Leicester, LE1 7HB, UK.

Juvenal Dario Baena Acevedo (JD)

Leicester Cancer Research Centre, University of Leicester, Leicester, LE2 7LX, UK.

Samantha Sinnadurai (S)

Leicester Cancer Research Centre, University of Leicester, Leicester, LE2 7LX, UK.

Claire Smith (C)

MRC Toxicology Unit, University of Cambridge, Leicester, LE1 7HB, UK.
Leicester Cancer Research Centre, University of Leicester, Leicester, LE2 7LX, UK.

Abi McSweeney (A)

Leicester Cancer Research Centre, University of Leicester, Leicester, LE2 7LX, UK.

Xiaoyu Su (X)

Leicester Cancer Research Centre, University of Leicester, Leicester, LE2 7LX, UK.

Leah Officer (L)

MRC Toxicology Unit, University of Cambridge, Leicester, LE1 7HB, UK.

Carolyn Jones (C)

MRC Toxicology Unit, University of Cambridge, Leicester, LE1 7HB, UK.

Kate Dudek (K)

MRC Toxicology Unit, University of Cambridge, Leicester, LE1 7HB, UK.

David Guttery (D)

Leicester Cancer Research Centre, University of Leicester, Leicester, LE2 7LX, UK.

Phillipe Taniere (P)

Cellular Pathology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, B15 2TH, UK.

Ruth V Spriggs (RV)

MRC Toxicology Unit, University of Cambridge, Leicester, LE1 7HB, UK.

John Le Quesne (J)

MRC Toxicology Unit, University of Cambridge, Leicester, LE1 7HB, UK. jlq2@le.ac.uk.
Leicester Cancer Research Centre, University of Leicester, Leicester, LE2 7LX, UK. jlq2@le.ac.uk.
Cellular Pathology, University Hospitals Leciester NHS Trust, Leciester, LE1 5WW, UK. jlq2@le.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH